News

Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.

However, the post-hoc analysis found a greater variability in HbA1c levels was associated with increased risk of cardiorenal outcomes.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.

A recent study, conducted by CreakyJoints, demonstrated that patient-reported satisfaction is affected by both social and cultural norms in Spanish-speaking patients with rheumatoid arthritis.

In recent years more and more biologics have come on the market for the treatment of IBD.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2022.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

A Montefiore residency director explains the impact of engaging with communities to improve mental health care capability.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.

Expert Dr. Mikkael Sekeres treats patients with bone marrow diseases and in this episode he talks about treatment methods, clinical trial obstacles and the importance of reliable sources when it comes to rare conditions like MDS and AML.

Uninsured adults with low income in nonexpansion states experienced worse access and cardiovascular risk factor management compared to insured adults.

Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."

Prematurity was also linked to infant regurgitation, infant colic, infant dysphasia, and functional constipation.

Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Thinning across the PMB associated with poorer VA at 9 months’ corrected age, independent of gestational age and macular microanatomy.

In data presented at DDW, there was no evidence found showing biologics result in an increased risk of developing malignancies for patients with IBD and PSC.

For pediatric patients, the anti-HBs (+) rates were relatively stable at approximately 60%, but the anti-HBc (+) rates increased significantly with age.

Dr. Eliseo Pascual's presentation at EULAR 2022 serves as a reminder to consider gender bias during the diagnosis, treatment, and management of rheumatic diseases.

HDL-C level >80 mg/dL was associated with higher risk of all-cause and cardiovascular death in patients with CAD, compared with those with normal HDL-C levels.

Montefiore's Carol A. Bernstein, MD, discusses the role of psychiatry specialists in discerning their colleagues' need for mental health care or resolutions to burnout.

The majority of treatment emergent adverse events were mild to moderate in severity.

The study authors suggest a thinner macular RNFL may predict a decline in cognitive performance.

John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.

Despite being rare, little is known regarding the pathophysiology of DLLR following COVID-19 vaccination.

Consultation aids can elevate communication around rheumatic and musculoskeletal disease, therefore promoting shared decision making between patients and clinicians.

Dr. Brown and Mr. Zavodnick speak on the first and only FDA-approved steroid-free topical medication in its class approved for psoriasis, and the data that bolstered this approval.

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Severe or inflammatory acne can result in prominent scarring in affected patients, which highlights the importance of grading acne in diagnosis of the skin condition.